0001493152-23-043009.txt : 20231129 0001493152-23-043009.hdr.sgml : 20231129 20231129092443 ACCESSION NUMBER: 0001493152-23-043009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231129 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ensysce Biosciences, Inc. CENTRAL INDEX KEY: 0001716947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822755287 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38306 FILM NUMBER: 231448804 BUSINESS ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 263-4196 MAIL ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Leisure Acquisition Corp. DATE OF NAME CHANGE: 20170913 8-K 1 form8-k.htm
false 0001716947 0001716947 2023-11-29 2023-11-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 29, 2023 (November 28, 2023)

 

Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38306   82-2755287

(State or other jurisdiction

of incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

   92037
(Address of principal executive offices)   (Zip Code)

 

(858) 263-4196

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENSC   The Nasdaq Stock Market LLC

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

As previously reported on a Current Report on Form 8-K filed October 24, 2023, on October 23, 2023, Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) entered into a Securities Purchase Agreement (the “SPA”) for an aggregate financing of $1.7 million with investors. At the first closing under the SPA, which occurred on October 25, 2023, the Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $612,000 for an aggregate purchase price of $566,667 (collectively, the “Notes”) and (ii) warrants (collectively, the “Warrants”) to purchase 1,255,697 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) in the aggregate. At a second closing under the SPA, which occurred on November 28, 2023 with funding occurring on November 29, 2023, the Company issued to the investors referenced above, (i) Notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333 and (i) Warrants to purchase 2,511,394 shares of the Common Stock in the aggregate.

 

The Notes, subject to an original issue discount of eight percent (8%), have a term of six months from their respective date of issuance and accrue interest at the rate of 6.0% per annum. The Notes are convertible into the Common Stock, at a per share conversion price equal to $1.5675. Beginning ninety days following issuance of the respective Notes, the Company is obligated to redeem monthly one third (1/3rd) of the original principal amount under the applicable Note, plus accrued but unpaid interest, liquidated damages and any other amounts then owing to the holder of such Note. The Company is required to pay the redemption amount in cash with a premium of ten percent or, at the election of the purchaser at any time, some or all of the principal amount and interest may be paid by conversion of shares under the Note into Common Stock based on a conversion price equal to $1.5675.

 

The Warrants have an exercise price of $1.5675, the same as the conversion price, and are exercisable for five years following issuance, issuance occurring on each of the first and second closing dates under the SPA.

 

The Company has registered with the Securities and Exchange Commission (the “SEC”) the resale of the shares of Common Stock issuable upon conversion of the Notes as well as the shares of Common Stock issuable upon the exercise of the Warrants.

 

The Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, each dated October 25, 2023, by and among the Company, the subsidiaries of the Company and the holders of the Notes and (ii) guaranteed jointly and severally by the subsidiaries of the Company pursuant to the Subsidiary Guarantee, dated October 25, 2023, by and among the Company, the subsidiaries of the Company and the purchasers signatory to the SPA.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The information provided under Item 1.01 in this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

Item 3.02. Unregistered Sales of Equity Securities

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The Notes and the Warrants were issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), based on the exemption from registration afforded by Section 4(a)(2) of the Securities Act.

 

2

 

 

Item 7.01. Regulation FD Disclosure.

 

On November 28, 2023, we issued a press release announcing the financing transaction described in this Current Report on Form 8-K. A copy of the press release is furnished herewith as Exhibit 99.1.

 

The information under this Item 8.01, including Exhibit 99.1, is deemed “furnished” and not “filed” under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Cautionary Statements

 

This filing includes “forward-looking statements.” All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Actual results could vary significantly from those expressed or implied in such statements and are subject to a number of risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that affect the Company’s operations, financial performance, and other factors as discussed in the Company’s filings with the SEC. Among the factors that could cause results to differ materially are those risks discussed in the periodic reports the Company files with the SEC. You are urged to carefully review and consider the cautionary statements and other disclosures made in those filings, specifically those under the heading “Risk Factors.” The Company does not undertake any duty to update any forward-looking statement except as required by law.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
4.6(a)   Form of Senior Secured Convertible Promissory Note to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement (incorporated by reference to Exhibit 4.6 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
4.6(b)   Form of First Amendment to the Senior Secured Convertible Note)
4.7   Form of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement (incorporated by reference to Exhibit 4.16 filed with the registrant’s Registration Statement on Form S-1 (File No. 333-275456) on November 17, 2023)
10.1†   Securities Purchase Agreement, dated October 23, 2023, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
10.2   Form of Registration Rights Agreement to be entered into by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
10.3   Form of Subsidiary Guarantee to be entered into by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
10.4†   Form of Security Agreement to be entered into by and among the Company, EBI OpCo, Inc., EBI, Inc. and the other parties signatory thereto (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
10.5†   Form of Patent Security Agreement, to be entered into by and among the Company, EBI OpCo, Inc., EBI, Inc. and the other parties signatory thereto (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023)
99.1   Press Release, dated November 28, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

† Schedules, exhibits and similar supporting attachments to this exhibit are omitted pursuant to Item 601(b)(2) of Regulation S-K. We agree to furnish a supplemental copy of any omitted schedule or similar attachment to the SEC upon request.

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 28, 2023

 

  Ensysce Biosciences, Inc.
     
  By: /s/ Lynn Kirkpatrick
  Name:  Dr. Lynn Kirkpatrick
  Title: President and Chief Executive Officer

 

4

 

 EX-4.6B 2 ex4-6b.htm

 

Exhibit 4.6(b)

 

FIRST AMENDMENT TO
SENIOR SECURED CONVERTIBLE NOTE

 

This First Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of November 28, 2023 (the “Effective Date”) is entered into by and between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and __________ (the “Purchaser”).

 

RECITALS

 

A. The Purchaser and the Company entered into that certain Securities Purchase Agreement dated as of October 23, 2023 (the “Original Agreement”), pursuant to which the Company agreed to sell and issue to each Purchaser, a senior secured convertible note (each, a “Original Note” and collectively, the “Original Notes”), convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in an aggregate principal amount of up to $1,700,000.

 

B. Pursuant to the Original Agreement, the Company issued to the Purchaser the Original Note in an original principal amount of $______ on October 25, 2023 but incorrectly dated the Original Note as of October 24, 2023.

 

C. The Purchaser and the Company desire to correct and amend the Original Note pursuant to and in accordance with the terms set forth herein.

 

D. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Original Note and Original Agreement.

 

AGREEMENT

 

NOW THEREFORE, in consideration of the foregoing, and the covenants and agreements herein contained, and for other good and valuable consideration, the mutual receipt and legal sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

1. Correction. The Original Issue Date set forth on the face of the Original Note is hereby changed from October 24, 2023 to October 25, 2023 and the four references in the Original Note and ANNEX A thereto are hereby changed from April 24, 2024 to April 25, 2024.

 

2. Amendment. The definition of the Monthly Redemption Date in Section 1 of the Original Note is hereby deleted in its entirety and replaced by the following:

 

“Monthly Redemption Date” means (i) with respect to the first (1st) Monthly Redemption, January 25, 2024, and (ii) with respect to all Monthly Redemptions subsequent to the first Monthly Redemption, February 25, 2024 and March 25, 2024, and terminating upon the full redemption of this Note.

 

3. Miscellaneous.

 

(a) Waivers and Amendments. Any provision of this Amendment may be amended, waived or modified only upon the written consent of the Company and the Purchaser.

 

(b) Entire Agreement. This Amendment together with the Original Note constitutes the entire agreement of the Company and the Purchaser with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, between the Company and Purchaser with respect to the subject matter hereof. Except as amended by this Amendment, the Original Note shall continue in full force and effect.

 

(c) Counterparts. This Amendment may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals.

 

[Remainder of page intentionally left blank; signature page follows.]

 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  COMPANY:
     
  ENSYSCE BIOSCIENCES, INC.
     
  By:  
  Name: Lynn Kirkpatrick
  Title: CEO

 

Signature Page to First Amendment to Original Note

 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER:
              
  By:  
  Name:  

 

Signature Page to First Amendment to Original Note

 

 

 

 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing

 

~ Additional Funding from Investors Validates Company’s Mission ~

 

SAN DIEGO, CA, November 28, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has completed its previously announced private placement under a securities purchase agreement (the “SPA”) with investors (“Investors”) for senior secured convertible notes (the “Notes”) and warrants exercisable for Ensysce common stock (the “Warrants”) for an aggregate investment of $1.7 million. The second funding by the Investors of $1,333,333.33, prior to fees and offering expenses, was dated as of November 28, 2023, with funds received in full on November 29, 2023.

 

Dr. Lynn Kirkpatrick, CEO of Ensysce commented, “The completion of this financing is another validation of our highly unique TAAP and MPAR® technologies. The funding will support the completion of a time of onset study and regulatory milestones for PF614, our lead product. We are very pleased that we were able to secure this additional funding that will complement the Federal Government Grant awards we receive that are progressing our MPAR and Opioid Use Disorder program. The funds from this second closing will continue our clinical progress with PF614 and support our mission to deliver superior pain relief options while also providing abuse and overdose protection for opioid products.”

 

As previously reported, the Notes, with total gross proceeds of $1.7 million before fees and expenses, are convertible into shares of Ensysce common stock (“Common Stock”) at a conversion price of $1.5675, the base price set at the time of execution of the SPA. The Notes have a maturity date of 6 months from the applicable closing date, will be issued with an original discount of 8% and will bear interest from date of issuance at 6% per annum. Monthly principal payments and interest in cash, or at the election of the purchaser in whole or in part which may occur at any time, in common stock will begin approximately 90 days after each respective closing. The Warrants issued at the initial closing provided for the right to purchase up to 1,255,697 shares of common stock at an exercise price of $1.5675, the same as the conversion price, and are exercisable for five years following the date of issuance. The Warrants issued at the second closing provided for the right to purchase up to 2,511,394 shares of common stock at the same exercise price, exercisable for five years following the date of issuance. An initial $566,667 of funding was secured upon the initial closing and $1,133,333 of additional funding was secured at the second closing.

 

The conversion price for the Notes of $1.5675 and the exercise price for the Warrants of $1.5675 meet a minimum price requirement established by The Nasdaq Stock Market in connection with a potential issuance of 20% or more of the common stock of a public company or 20% or more of the voting power outstanding before the potential issuance. If the Company is not able to pay the principal and interest on the Notes when due and the Company needs to issue more shares of Common Stock or on terms different than those provided by the transaction documents, the Company might, in certain circumstances, be required to obtain stockholder approval before doing so.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

 

About Ensysce Biosciences

 

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

 

 

 

 

Forward-Looking Statements

 

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

 

Ensysce Biosciences Company Contact:

 

Lynn Kirkpatrick, Ph.D.

Chief Executive Officer

(858) 263-4196

 

Ensysce Biosciences Investor Relations Contact:

 

Shannon Devine

MZ North America

Main: 203-741-8811

ENSC@mzgroup.us

 

Source: Ensysce Biosciences Inc.

 

 

 

 EX-101.SCH 4 ensc-20231129.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ensc-20231129_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ensc-20231129_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 29, 2023
Entity File Number 001-38306
Entity Registrant Name Ensysce Biosciences, Inc.
Entity Central Index Key 0001716947
Entity Tax Identification Number 82-2755287
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7946 Ivanhoe Avenue
Entity Address, Address Line Two Suite 201
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 263-4196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ENSC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001716947 2023-11-29 2023-11-29 iso4217:USD shares iso4217:USD shares false 0001716947 8-K 2023-11-29 Ensysce Biosciences, Inc. DE 001-38306 82-2755287 7946 Ivanhoe Avenue Suite 201 La Jolla CA 92037 (858) 263-4196 false false false false Common Stock, par value $0.0001 per share ENSC NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ensysce.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ensc-20231129.xsd ensc-20231129_lab.xml ensc-20231129_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "ENSC", "nsuri": "http://ensysce.com/20231129", "dts": { "schema": { "local": [ "ensc-20231129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ensc-20231129_lab.xml" ] }, "presentationLink": { "local": [ "ensc-20231129_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://ensysce.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ensysce.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-043009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-043009-xbrl.zip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